CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers – Compensatory Arrangements of Certain Officers.
On May 3, 2018, CytRx Corporation ("we," "us," "our," "CytRx," or the "Company") issued a press release announcing that our Board of Directors, at its regular meeting held on May 2, 2018, has approved the appointment of Mr. Eric L. Curtis, who is 50 years old, to the Company's executive management team, as President and Chief Operating Officer, effective May 3, 2018. He brings 25 years of life science development and operational experience to CytRx, with a proven track record in oncology and orphan diseases. Mr. Curtis will assume a leadership role in the partnering of CytRx's proprietary LADR™ technology and advancing the Company's current programs and future discoveries.
Mr. Curtis holds a Master of Business Administration degree from Pennsylvania State University. He earned his Bachelor of Science degree in both Business and Psychology, from the University of Pittsburgh.
A copy of the press release is attached hereto as Exhibit 99 and incorporated herein by reference. Mr. Curtis is not related by birth or marriage to any employees or directors at CytRx. During the past five years prior to his employment at CytRx, Mr. Curtis was employed as President, U.S. Commercial, at Aegerion Pharmaceuticals (now Novelion Therapeutics) and provided strategic consultancy services to a variety of healthcare-focused companies, including CytRx, through his own company, Curtis Biopharm Consulting. The terms of Mr. Curtis's compensation and his employment contract are still being negotiated and will be filed by the Company when available..
Item 9.01.Financial Statements and Exhibits
(d)Exhibits
There is filed as part of this report, the exhibit listed on the accompanying Exhibit Index, which information is incorporated herein by reference.
CYTRX CORP ExhibitEX-99 2 exh99.htm PRESS RELEASE OF CYTRX CORPORATION ISSUED MAY 3,…To view the full exhibit click here
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
